By Scientia Professor Vlado Perkovic

Journal articles

Perkovic V; Barratt J; Radhakrishnan J; Rizk D; Trimarchi H; Khawaja Z; Leiske J; Sorensen B; King A; Jones-Burton C; Campbell K, 2023, '#4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063c_4333

Charytan DM; Mahaffey KW; Jardine MJ; Cannon CP; Neal B; Lambers Heerspink HJ; Agarwal R; Bakris GL; De Zeeuw D; Levin A; Pollock C; Zhang H; Zinman B; Rosenthal N; Perkovic V; Di Tanna GL; Yu J; Rogers K; Arnott C; Wheeler DC, 2023, 'Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering', BMJ Open Diabetes Research and Care, 11, pp. e003270, http://dx.doi.org/10.1136/bmjdrc-2022-003270

Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N, 2023, 'Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis', Nephrology Dialysis Transplantation, 38, pp. 1448 - 1458, http://dx.doi.org/10.1093/ndt/gfac289

van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL, 2023, 'Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial', Clinical journal of the American Society of Nephrology : CJASN, 18, pp. 748 - 758, http://dx.doi.org/10.2215/CJN.0000000000000161

Heerspink HJL; Radhakrishnan J; Alpers CE; Barratt J; Bieler S; Diva U; Inrig J; Komers R; Mercer A; Noronha IL; Rheault MN; Rote W; Rovin B; Trachtman H; Trimarchi H; Wong MG; Perkovic V; Alarmartine E; Chae DW; Del Vecchio L; Floege J; Hwang SJ; Jelakovic B; Maes B; Malecki R; Miglinas M; Nolasco FEB; Praga M; Rabindranath K; Rosenberg M; Tang SCW; Tesar V; Bose B; Gangadharan M; McDonald S; Peh C; Jahan S; Yeap C; Clayton P; Irish G; Thyagarajan N; Hollett P; Krishnasamy R; Carroll R; Jesudason S; Crail S; Coates T; Waugh J; Noble E; Mahadevan K; Campbell V; Salehi T; Lim W; Boudville N; Chakera A; Chan D; Krishnan A; Eqbal Y; Gillies A; Vilayur E; Maung Myint TM; Gray N; Cheetham M; Pollock C; Cooper B; Mather A; Roxburgh S; Shen Y; Stangenberg S; Siriwardana A; O'Lone E; Wan S; Neuen B; Tsun Kit Ha J; Kim D; Heath L; Jain A; Phua E; Li Y; Gallagher M; Jardine M; Ritchie A; Razavian M; Foote C; Wyndham R; Sen S; Endre Z; Erlich J; Fernando M; Yong K; Luxton G; Kotwal S; Roger S; Wijeratne V; Packham D; Fraser I; Vandewiele B; Laute M; Lemahieu W; Jamar S, 2023, 'Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial', The Lancet, 401, pp. 1584 - 1594, http://dx.doi.org/10.1016/S0140-6736(23)00569-X

Koshino A; Oshima M; Arnott C; Fletcher RA; Bakris GL; Jardine M; Mahaffey KW; Perkovic V; Pollock C; Heerspink HJL; Neuen BL, 2023, 'Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 1413 - 1418, http://dx.doi.org/10.1111/dom.14978

Barratt J; Rovin B; Wong MG; Alpers CE; Bieler S; He P; Inrig J; Komers R; Heerspink HJL; Mercer A; Noronha IL; Radhakrishnan J; Rheault MN; Rote W; Trachtman H; Trimarchi H; Perkovic V, 2023, 'IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study', Kidney International Reports, 8, pp. 1043 - 1056, http://dx.doi.org/10.1016/j.ekir.2023.02.1086

Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J, 2023, 'Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study', Kidney International Reports, 8, pp. 968 - 979, http://dx.doi.org/10.1016/j.ekir.2023.01.041

Zhang YM; Lv JC; Wong MG; Zhang H; Perkovic V, 2023, 'Glucocorticoids for IgA nephropathy—pro', Kidney International, 103, pp. 666 - 669, http://dx.doi.org/10.1016/j.kint.2023.01.018

Neuen BL; Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang GE; Bellorin-Font E; Gharbi MB; Davison S; Ghnaimat M; Harden P; Jha V; Kalantar-Zadeh K; Kerr PG; Klarenbach S; Kovesdy CP; Luyckx V; Ossareh S; Perl J; Rashid HU; Rondeau E; See EJ; Saad S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Kazancioglu RT; Wang AYM; Yang CW; Zemchenkov A; Zhao MH; Jager KJ; Caskey FJ; Perkovic V; Jindal KK; Okpechi IG; Tonelli M; Feehally J; Harris DC; Johnson DW, 2023, 'National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas', PLOS Global Public Health, 3, http://dx.doi.org/10.1371/journal.pgph.0001467

Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW, 2023, 'Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial', International Journal of Cardiology, 395, http://dx.doi.org/10.1016/j.ijcard.2023.131444

Heerspink HJ; Agarwal R; Bakris GL; Cherney D; Lam CSP; Neuen BL; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen PH; Perkovic V, 2023, 'Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD', Journal of the American Society of Nephrology, 34, pp. 678 - 678, http://dx.doi.org/10.1681/asn.20233411s1678a

Tangri N; Ferguson TW; Bamforth RJ; Arnott CG; Mahaffey KW; Heerspink HJ; Perkovic V; Neuen BL, 2023, 'External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials', Journal of the American Society of Nephrology, 34, pp. 418 - 419, http://dx.doi.org/10.1681/asn.20233411s1418c

Ha J; Hiremath S; Jun M; Palmer S; Wheeler DC; Coyne DW; Perkovic V; Badve S, 2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', Journal of the American Society of Nephrology, 34, pp. 367 - 367, http://dx.doi.org/10.1681/asn.20233411s1367a

Jun M; Wick J; Neuen BL; Kotwal SS; Badve S; Chalmers JP; Jardine M; Perkovic V; Gallagher MP; Ronksley PE, 2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Journal of the American Society of Nephrology, 34, pp. 373 - 373, http://dx.doi.org/10.1681/asn.20233411s1373a

Jain SS; Yu J; Arnott C; Neal BC; Perkovic V; Neuen B; Jardine M; Mahaffey KW, 2023, 'TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL', Journal of the American College of Cardiology, 81, pp. 283, http://dx.doi.org/10.1016/s0735-1097(23)00727-1

KIM D; Lv J; Hladunewich M; Jha V; Hooi LS; Monaghan H; Billot L; Zhang H; Perkovic V; Wong MG, 2023, 'WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL', Kidney International Reports, 8, pp. S51 - S52, http://dx.doi.org/10.1016/j.ekir.2023.02.118

Barratt J; Rovin BH; Zhang H; Rizk DV; Kashihara N; Maes BD; Trimarchi H; Sprangers B; Meier M; Kollins D; Junge G; Milojevic J; Papachristofi O; Perkovic V, 2023, 'WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY', Kidney International Reports, 8, pp. S271 - S272, http://dx.doi.org/10.1016/j.ekir.2023.02.612

TALBOT B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Knight J, 2023, 'WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY', Kidney International Reports, 8, pp. S350 - S350, http://dx.doi.org/10.1016/j.ekir.2023.02.786

Mc Causland FR; Singh AK; Claggett BL; Carroll K; Wittes J; McMurray JJV; Perkovic V; Snapinn S; Lopes RD; Solomon SD, 2022, 'Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply', The New England journal of medicine, 387, pp. 2482 - 2485, http://dx.doi.org/10.1056/NEJMc2208182

Ridker PM; Tuttle KR; Perkovic V; Libby P; Macfadyen JG, 2022, 'Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy', European Heart Journal, 43, pp. 4832 - 4844, http://dx.doi.org/10.1093/eurheartj/ehac444

Nunes JC; Yu J; Arnott C; Jardine MJ; Perkovic V; Mahaffey KW, 2022, 'Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program', Diabetes, Obesity and Metabolism, 24, pp. 2459 - 2464, http://dx.doi.org/10.1111/dom.14832

Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL, 2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure', Cardiovascular Diabetology, 21, pp. 194, http://dx.doi.org/10.1186/s12933-022-01619-0

Hammett C; Badve SV; Kerr PG; Tran HA; Dundon BK; Lo S; Wong A; Joseph JE; Deague J; Perkovic V, 2022, 'Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice', Heart Lung and Circulation, 31, pp. 1604 - 1611, http://dx.doi.org/10.1016/j.hlc.2022.09.003

Baigent C; Emberson JR; Haynes R; Herrington WG; Judge P; Landray MJ; Mayne KJ; Ng SYA; Preiss D; Roddick AJ; Staplin N; Zhu D; Anker SD; Bhatt DL; Brueckmann M; Butler J; Cherney DZI; Green JB; Hauske SJ; Heerspink HJL; Inzucchi SE; Jardine MJ; Liu CC; Mahaffey KW; McCausland FR; McGuire DK; McMurray JJV; Neal B; Neuen BL; Packer M; Perkovic V; Sabatine MS; Solomon SD; Vaduganathan M; Wanner C; Wheeler DC; Wiviott SD; Zannad F, 2022, 'Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials', The Lancet, 400, pp. 1788 - 1801, http://dx.doi.org/10.1016/S0140-6736(22)02074-8

Kolkailah AA; Marx N; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto R; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK, 2022, 'Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin', Circulation, 146, http://dx.doi.org/10.1161/circ.146.suppl_1.12404

Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW, 2022, 'Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria', Journal of the American College of Cardiology, 80, pp. 1721 - 1731, http://dx.doi.org/10.1016/j.jacc.2022.08.772

Koshino A; Schechter M; Sen T; Vart P; Neuen BL; Neal B; Arnott C; Perkovic V; Ridker PM; Tuttle KR; Hansen MK; Heerspink HJL, 2022, 'Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS', Diabetes Care, 45, pp. 2644 - 2652, http://dx.doi.org/10.2337/dc22-0866

Smeijer JD; Koomen JV; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Kitzman DW; Makino H; Mayer G; Nowicki M; Perkovic V; Rossing P; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL, 2022, 'Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease', Clinical Pharmacology and Therapeutics, 112, pp. 1098 - 1107, http://dx.doi.org/10.1002/cpt.2721

Perkovic V; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Dimino TL; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; Mcmurray JJV; Meadowcroft AM; Obrador GT; Solomon S; Taft L; Wanner C; Waikar SS; Wheeler DC; Wiecek A; Singh AK, 2022, 'The ASCEND-ND trial: study design and participant characteristics', Nephrology Dialysis Transplantation, 37, pp. 2157 - 2170, http://dx.doi.org/10.1093/ndt/gfab318

Mahaffey KW; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Lawson J; Mann JFE; Mersebach H; Perkovic V; Rossing P; Tuttle K; Pratley R, 2022, 'Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.2617

Singh AK; Acharya A; Carroll K; Lopes RD; McCausland FR; Mulloy L; Perkovic V; Solomon S; Waikar SS; Wanner C; Wong MG; Cobitz AR; Mallett SA; Shaddinger BC; McMurray JJV, 2022, 'Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.1053

McCausland F; Singh A; Claggett B; Carroll K; Wittes J; McMurray JJV; Perkovic V; Snappin S; Lopes R; Solomon S, 2022, 'Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.2621

Li C; Yu J; Hockham C; Perkovic V; Neuen BL; Badve SV; Houston L; Lee VYJ; Barraclough JY; Fletcher RA; Mahaffey KW; Heerspink HJL; Cannon CP; Neal B; Arnott C, 2022, 'Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis', Diabetes, Obesity and Metabolism, 24, pp. 1927 - 1938, http://dx.doi.org/10.1111/dom.14772

Wong MG; Lv J; Perkovic V, 2022, 'Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy - Reply', JAMA, 328, pp. 1108 - 1109, http://dx.doi.org/10.1001/jama.2022.12712

Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K; Agodoa L; Algra A; Asselbergs FW; Beckett N; Berge E; Black H; Brouwers FPJ; Brown M; Bulpitt CJ; Byington B; Cutler J; Devereaux RB; Dwyer J; Estacio R; Fagard R; Fox K; Fukui T; Imai Y; Ishii M; Julius S; Kanno Y; Kjeldsen SE; Kostis J; Kuramoto K; Lanke J; Lewis E; Lewis J; Lievre M; Lindholm LH; Lueders S; MacMahon S; Mancia G; Matsuzaki M; Mehlum MH; Nissen S; Ogawa H; Ogihara T; Ohkubo T; Palmer C; Patel A; Pfeffer M; Poulter NR; Rakugi H; Reboldi G; Reid C; Remuzzi G; Ruggenenti P; Saruta T; Schrader J; Schrier R; Sever P; Sleight P; Staessen JA; Suzuki H; Thijs L; Ueshima K; Umemoto S; van Gilst WH; Verdecchia P; Wachtell K; Whelton P; Wing L; Yui Y; Yusuf S; Zanchetti A; Zhang ZY; Anderson C; Baigent C; Brenner BM; Collins R; de Zeeuw D; Lubsen J; Malacco E; Neal B; Perkovic V; Pitt B; Rodgers A; Rothwell P; Salimi-Khorshidi G; Sundström J, 2022, 'Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis', The Lancet Diabetes and Endocrinology, 10, pp. 645 - 654, http://dx.doi.org/10.1016/S2213-8587(22)00172-3

Li JW; Arnott C; Heerspink HJL; Mbiostat QL; Cannon CP; Wheeler DC; Charytan DM; Barraclough J; Figtree GA; Agarwal R; Bakris G; de Zeeuw D; Greene T; Levin A; Pollock C; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Neal B; Jardine MJ, 2022, 'Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial', Journal of the American Heart Association, 11, pp. e025045, http://dx.doi.org/10.1161/JAHA.121.025045

Ferrannini E; Baldi S; Scozzaro T; Tsimihodimos V; Tesfaye F; Shaw W; Rosenthal N; Figtree GA; Neal B; Mahaffey KW; Perkovic V; Hansen MK, 2022, 'Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)', Diabetes Care, 45, pp. 1893 - 1899, http://dx.doi.org/10.2337/dc21-2398

Heerspink HJL; Stack AG; Terkeltaub R; Greene TA; Inker LA; Bjursell M; Perl S; Rikte T; Erlandsson F; Perkovic V, 2022, 'Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia', Nephrology Dialysis Transplantation, 37, pp. 1461 - 1471, http://dx.doi.org/10.1093/ndt/gfab237

Smeijer JD; Koomen J; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Januzzi JL; Kitzman DW; Kolansky DM; Makino H; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL, 2022, 'Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure', JACC: Heart Failure, 10, pp. 498 - 507, http://dx.doi.org/10.1016/j.jchf.2022.03.004

Kotwal S; Perkovic V; Heerspink HJL, 2022, 'Platform Clinical Trials Within Nephrology—Interpreting the Evidence', American Journal of Kidney Diseases, 80, pp. 143 - 146, http://dx.doi.org/10.1053/j.ajkd.2022.01.430

Liao J; Kang A; Xia C; Young T; Di Tanna GL; Arnott C; Pollock C; Krishnan AV; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B, 2022, 'The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial', Diabetes and Metabolism, 48, pp. 101331, http://dx.doi.org/10.1016/j.diabet.2022.101331

Barraclough JY; Yu J; Figtree GA; Perkovic V; Heerspink HJL; Neuen BL; Cannon CP; Mahaffey KW; Schutte AE; Neal B; Arnott C, 2022, 'Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 24, pp. 1072 - 1083, http://dx.doi.org/10.1111/dom.14671

Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S, 2022, 'Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial', JAMA Internal Medicine, 182, pp. 592 - 602, http://dx.doi.org/10.1001/jamainternmed.2022.0605

Waijer SW; Provenzano M; Mulder S; Rossing P; Persson F; Perkovic V; Heerspink HJL, 2022, 'Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology', Diabetes, Obesity and Metabolism, 24, pp. 983 - 990, http://dx.doi.org/10.1111/dom.14660

Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2022, 'Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial', JAMA - Journal of the American Medical Association, 327, pp. 1888 - 1898, http://dx.doi.org/10.1001/jama.2022.5368

Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL, 2022, 'Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized, Controlled Trials', Circulation, 145, pp. 1460 - 1470, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057736

Singh AK; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Perkovic V; Solomon S; Wanner C; Waikar SS; Wheeler DC; Wiecek A, 2022, 'Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial', Nephrology Dialysis Transplantation, 37, pp. 960 - 972, http://dx.doi.org/10.1093/ndt/gfab065

Feng Y; Li Q; Finfer S; Myburgh J; Bellomo R; Perkovic V; Jardine M; Wang AY; Gallagher M, 2022, 'A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation', Frontiers in Cardiovascular Medicine, 9, http://dx.doi.org/10.3389/fcvm.2022.840611

Shaman AM; Bain SC; Bakris GL; Buse JB; Idorn T; Mahaffey KW; Mann JFE; Nauck MA; Rasmussen S; Rossing P; Wolthers B; Zinman B; Perkovic V, 2022, 'Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER', Circulation, 145, pp. 575 - 585, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.055459

Back to profile page